Over the past decade, CRISPR has become as much a verb as it is an acronym,
transforming biomedical research and providing entirely new approaches for dissecting all …

In vivo gene editing therapies offer the potential to treat the root causes of many genetic
diseases. Realizing the promise of therapeutic in vivo gene editing requires the ability to …

Cell-based therapeutics are an emerging modality with the potential to treat many currently
intractable diseases through uniquely powerful modes of action. Despite notable recent …

Compact and versatile CRISPR-Cas systems will enable genome engineering applications
through high-efficiency delivery in a wide variety of contexts. Here, we create an efficient …

The engineering of autologous patient T cells for adoptive cell therapies has revolutionized
the treatment of several types of cancer. However, further improvements are needed to …

An outbreak of betacoronavirus severe acute respiratory syndrome (SARS)-CoV-2 began in
Wuhan, China in December 2019. COVID-19, the disease associated with SARS-CoV-2 …

Base editing—the introduction of single-nucleotide variants (SNVs) into DNA or RNA in
living cells—is one of the most recent advances in the field of genome editing. As around …

Genome editing, which involves the precise manipulation of cellular DNA sequences to alter
cell fates and organism traits, has the potential to both improve our understanding of human …

INTRODUCTION Most cancers are recognized and attacked by the immune system but can
progress owing to tumor-mediated immunosuppression and immune evasion mechanisms …

The prokaryote-derived CRISPR–Cas genome editing systems have transformed our ability
to manipulate, detect, image and annotate specific DNA and RNA sequences in living cells …